Skip to main content
Quest Diagnostics

Viral Load Preemptive Monitoring in the Post-Transplant Immunocompromised Population

Viral Load Preemptive Monitoring in the Post-Transplant Immunocompromised Population

Authors: Liesman RM, Hijano DR, Uprety P, Dunn JJ

Citation: J Mol Diagn. 2026 Jan 23:S1525-1578(26)00008-5. doi: 10.1016/j.jmoldx.2026.01.004. Online ahead of print.

Specialties: Infectious disease, Transplant, Immunology

Related content

On-Demand Webinar
Rethinking the Basics of Post-transplant Infections
Publication
Burden and frequency of viral testing of kidney and non-kidney transplant recipients
Test FAQ
Donor Testing
Test FAQ
Cytomegalovirus (CMV) Genotype
Conference Presentation
Next-Generation Sequencing to Detect Drug-Resistant Cytomegalovirus Mutations

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.